Company intelligence
Revelyx Bio
Advancing differentiated clinical-stage therapies for global markets.
NASHVILLE, US
1 employees
3 public signals
About Revelyx Bio
Revelyx Bio is a clinical-stage biotechnology company advancing APAC innovation into the world’s largest markets. We identify differentiated therapeutic opportunities and scale them through disciplined clinical development, regulatory strategy, and chemistry, manufacturing and controls (CMC). Our initial focus is recombinant botulinum toxin type A (rBoNT/A) for aesthetic and therapeutic indications.
Verified activity
Signals from Revelyx Bio
3 published signals
Products & Services
Revelyx Bio is introducing a new product focused on identifying promising clinical-stage programs and bringing them to global markets.
Reported by Revelyx Bio
Strategy & Corporate Development
Revelyx Bio announced that in 2025, 40% of the assets in-licensed by large pharmaceutical companies had a Chinese licensor.
Reported by Dustin Sjuts
Presence & Recognition
Revelyx Bio announced that Asia now represents 43% of the global innovative biopharma pipeline, up from 28% five years ago.
Reported by Dustin Sjuts